All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On September 12–15 2018, the sixth annual meeting of the Society of Hematologic Oncology (SOHO) was held in Houston, Texas. The meeting covered a variety of topics in the latest advances in the pathophysiology and treatment of hematological malignancies.
Oral abstract NHL 088 was presented by Angelo Brito, University of Campinas, Sao Paulo, BR, entitled “Angiogenesis’ related polymorphism emerges as a prognostic marker in de novo large B-cell lymphoma patients”. The aim of the study by Brito, et al, was to evaluate if there was an association between vascular endothelial growth factor (VEGF)A and the type 2 receptor (VEGFR2) single nucleotide polymorphisms (SNPs) and the clinicopathological features and outcomes of patients with diffuse large B-cell lymphoma (DLBCL). The study also aimed to determine an association between VEGF and VEGFR2 SNPs with angiogenesis-related proteins by immunohistochemistry.
Dr Brito concluded that the data in the study showed an association between VEGF and VEGFR2 SNPs enrolled in the angiogenesis pathway with prognosis in patients with DLBCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox